schliessen

Filtern

 

Bibliotheken

Prospective Clinical Study of Precision Oncology in Solid Tumors

Systematic studies evaluating clinical benefit of tumor genomic profiling are lacking. We conducted a prospective study in 250 patients with select solid tumors at the Cleveland Clinic. Eligibility required histopathologic diagnosis, age of 18 years or older, Eastern Cooperative Oncology Group perfo... Full description

Journal Title: Journal Of The National Cancer Institute 2016, Vol. 108(3)
Main Author: Sohal, Davendra P. S
Other Authors: Rini, Brian I , Khorana, Alok A , Dreicer, Robert , Abraham, Jame , Procop, Gary W , Saunthararajah, Yogen , Pennell, Nathan A , Stevenson, James P , Pelley, Robert , Estfan, Bassam , Shepard, Dale , Funchain, Pauline , Elson, Paul , Adelstein, David J , Bolwell, Brian J
Format: Electronic Article Electronic Article
Language:
Subjects:
ID: ISSN: 0027-8874 ; E-ISSN: 1460-2105 ; DOI: 10.1093/jnci/djv332
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: oxford10.1093/jnci/djv332
title: Prospective Clinical Study of Precision Oncology in Solid Tumors
format: Article
creator:
  • Sohal, Davendra P. S
  • Rini, Brian I
  • Khorana, Alok A
  • Dreicer, Robert
  • Abraham, Jame
  • Procop, Gary W
  • Saunthararajah, Yogen
  • Pennell, Nathan A
  • Stevenson, James P
  • Pelley, Robert
  • Estfan, Bassam
  • Shepard, Dale
  • Funchain, Pauline
  • Elson, Paul
  • Adelstein, David J
  • Bolwell, Brian J
subjects:
  • Cancer Genetics -- Research
  • Precision Medicine -- Innovations
  • Cancer Treatment -- Innovations
  • Cancer Research
  • Genetic Research
ispartof: Journal Of The National Cancer Institute, 2016, Vol. 108(3)
description: Systematic studies evaluating clinical benefit of tumor genomic profiling are lacking. We conducted a prospective study in 250 patients with select solid tumors at the Cleveland Clinic. Eligibility required histopathologic diagnosis, age of 18 years or older, Eastern Cooperative Oncology Group performance status 0–2, and written informed consent. Tumors were sequenced using FoundationOne (Cambridge, MA). Results were reviewed at the Cleveland Clinic Genomics Tumor Board. Outcomes included feasibility and clinical impact. Colorectal (25%), breast (18%), lung (13%), and pancreatobiliary (13%) cancers were the most common diagnoses. Median time from consent to result was 25 days (range = 3–140). Of 223 evaluable samples, 49% (n = 109) of patients were recommended a specific therapy, but only 11% (n = 24) received such therapy: 12 on clinical trials, nine off-label, three on-label. Lack of clinical trial access (n = 49) and clinical deterioration (n = 29) were the most common reasons for nonrecommendation/nonreceipt of genomics-driven therapy.
language:
source:
identifier: ISSN: 0027-8874 ; E-ISSN: 1460-2105 ; DOI: 10.1093/jnci/djv332
fulltext: fulltext
issn:
  • 0027-8874
  • 00278874
  • 1460-2105
  • 14602105
url: Link


@attributes
ID1865910789
RANK0.07
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
LOCALfalse
PrimoNMBib
record
control
sourcerecordid10.1093/jnci/djv332
sourceidoxford
recordidTN_oxford10.1093/jnci/djv332
sourceformatXML
sourcesystemPC
pqid1732597893
galeid449417978
display
typearticle
titleProspective Clinical Study of Precision Oncology in Solid Tumors
creatorSohal, Davendra P. S ; Rini, Brian I ; Khorana, Alok A ; Dreicer, Robert ; Abraham, Jame ; Procop, Gary W ; Saunthararajah, Yogen ; Pennell, Nathan A ; Stevenson, James P ; Pelley, Robert ; Estfan, Bassam ; Shepard, Dale ; Funchain, Pauline ; Elson, Paul ; Adelstein, David J ; Bolwell, Brian J
ispartofJournal Of The National Cancer Institute, 2016, Vol. 108(3)
identifier
descriptionSystematic studies evaluating clinical benefit of tumor genomic profiling are lacking. We conducted a prospective study in 250 patients with select solid tumors at the Cleveland Clinic. Eligibility required histopathologic diagnosis, age of 18 years or older, Eastern Cooperative Oncology Group performance status 0–2, and written informed consent. Tumors were sequenced using FoundationOne (Cambridge, MA). Results were reviewed at the Cleveland Clinic Genomics Tumor Board. Outcomes included feasibility and clinical impact. Colorectal (25%), breast (18%), lung (13%), and pancreatobiliary (13%) cancers were the most common diagnoses. Median time from consent to result was 25 days (range = 3–140). Of 223 evaluable samples, 49% (n = 109) of patients were recommended a specific therapy, but only 11% (n = 24) received such therapy: 12 on clinical trials, nine off-label, three on-label. Lack of clinical trial access (n = 49) and clinical deterioration (n = 29) were the most common reasons for nonrecommendation/nonreceipt of genomics-driven therapy.
source
subjectCancer Genetics -- Research ; Precision Medicine -- Innovations ; Cancer Treatment -- Innovations ; Cancer Research ; Genetic Research;
version7
lds50peer_reviewed
links
openurl$$Topenurl_article
openurlfulltext$$Topenurlfull_article
search
creatorcontrib
0Sohal, Davendra P. S
1Rini, Brian I
2Khorana, Alok A
3Dreicer, Robert
4Abraham, Jame
5Procop, Gary W
6Saunthararajah, Yogen
7Pennell, Nathan A
8Stevenson, James P
9Pelley, Robert
10Estfan, Bassam
11Shepard, Dale
12Funchain, Pauline
13Elson, Paul
14Adelstein, David J
15Bolwell, Brian J
titleProspective Clinical Study of Precision Oncology in Solid Tumors
descriptionSystematic studies evaluating clinical benefit of tumor genomic profiling are lacking. We conducted a prospective study in 250 patients with select solid tumors at the Cleveland Clinic. Eligibility required histopathologic diagnosis, age of 18 years or older, Eastern Cooperative Oncology Group performance status 0–2, and written informed consent. Tumors were sequenced using FoundationOne (Cambridge, MA). Results were reviewed at the Cleveland Clinic Genomics Tumor Board. Outcomes included feasibility and clinical impact. Colorectal (25%), breast (18%), lung (13%), and pancreatobiliary (13%) cancers were the most common diagnoses. Median time from consent to result was 25 days (range = 3–140). Of 223 evaluable samples, 49% (n = 109) of patients were recommended a specific therapy, but only 11% (n = 24) received such therapy: 12 on clinical trials, nine off-label, three on-label. Lack of clinical trial access (n = 49) and clinical deterioration (n = 29) were the most common reasons for nonrecommendation/nonreceipt of genomics-driven therapy.
general
010.1093/jnci/djv332
1Oxford Journals
sourceidoxford
recordidoxford10.1093/jnci/djv332
issn
00027-8874
100278874
21460-2105
314602105
rsrctypearticle
creationdate2016
searchscopeoxford
scopeoxford
lsr4020160301
lsr4120151109
lsr30VSR-Enriched:[galeid, pqid, subject]
sort
titleProspective Clinical Study of Precision Oncology in Solid Tumors
authorSohal, Davendra P. S ; Rini, Brian I ; Khorana, Alok A ; Dreicer, Robert ; Abraham, Jame ; Procop, Gary W ; Saunthararajah, Yogen ; Pennell, Nathan A ; Stevenson, James P ; Pelley, Robert ; Estfan, Bassam ; Shepard, Dale ; Funchain, Pauline ; Elson, Paul ; Adelstein, David J ; Bolwell, Brian J
creationdate20160300
facets
frbrgroupid-79859125396716025
frbrtype5
creationdate2016
collectionOxford Journals (Oxford University Press)
prefilterarticles
rsrctypearticles
creatorcontrib
0Sohal, Davendra P. S
1Rini, Brian I
2Khorana, Alok A
3Dreicer, Robert
4Abraham, Jame
5Procop, Gary W
6Saunthararajah, Yogen
7Pennell, Nathan A
8Stevenson, James P
9Pelley, Robert
10Estfan, Bassam
11Shepard, Dale
12Funchain, Pauline
13Elson, Paul
14Adelstein, David J
15Bolwell, Brian J
jtitleJournal Of The National Cancer Institute
toplevelpeer_reviewed
delivery
delcategoryRemote Search Resource
fulltextfulltext
addata
aulast
0Sohal
1Rini
2Khorana
3Dreicer
4Abraham
5Procop
6Saunthararajah
7Pennell
8Stevenson
9Pelley
10Estfan
11Shepard
12Funchain
13Elson
14Adelstein
15Bolwell
aufirst
0Davendra P. S.
1Brian I.
2Alok A.
3Robert
4Jame
5Gary W.
6Yogen
7Nathan A.
8James P.
9Bassam
10Dale
11Pauline
12Paul
13David J.
14Brian J.
au
0Sohal, Davendra P. S.
1Rini, Brian I.
2Khorana, Alok A.
3Dreicer, Robert
4Abraham, Jame
5Procop, Gary W.
6Saunthararajah, Yogen
7Pennell, Nathan A.
8Stevenson, James P.
9Pelley, Robert
10Estfan, Bassam
11Shepard, Dale
12Funchain, Pauline
13Elson, Paul
14Adelstein, David J.
15Bolwell, Brian J.
atitleProspective Clinical Study of Precision Oncology in Solid Tumors
jtitleJournal Of The National Cancer Institute
risdate201603
volume108
issue3
issn0027-8874
eissn1460-2105
formatjournal
genrearticle
ristypeJOUR
abstractSystematic studies evaluating clinical benefit of tumor genomic profiling are lacking. We conducted a prospective study in 250 patients with select solid tumors at the Cleveland Clinic. Eligibility required histopathologic diagnosis, age of 18 years or older, Eastern Cooperative Oncology Group performance status 0–2, and written informed consent. Tumors were sequenced using FoundationOne (Cambridge, MA). Results were reviewed at the Cleveland Clinic Genomics Tumor Board. Outcomes included feasibility and clinical impact. Colorectal (25%), breast (18%), lung (13%), and pancreatobiliary (13%) cancers were the most common diagnoses. Median time from consent to result was 25 days (range = 3–140). Of 223 evaluable samples, 49% (n = 109) of patients were recommended a specific therapy, but only 11% (n = 24) received such therapy: 12 on clinical trials, nine off-label, three on-label. Lack of clinical trial access (n = 49) and clinical deterioration (n = 29) were the most common reasons for nonrecommendation/nonreceipt of genomics-driven therapy.
pubOxford University Press
doi10.1093/jnci/djv332
date2016-03